Tiziana Life Sciences (NASDAQ:TLSA) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Earnings and Valuation
This table compares Tiziana Life Sciences and VBI Vaccines' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Tiziana Life Sciences | N/A | N/A | $-9,320,000.00 | ($0.03) | -93.00 |
| VBI Vaccines | $2.22 million | 333.64 | $-54,810,000.00 | ($0.46) | -6.65 |
Tiziana Life Sciences has higher earnings, but lower revenue than VBI Vaccines. Tiziana Life Sciences is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Tiziana Life Sciences has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500.
Profitability
This table compares Tiziana Life Sciences and VBI Vaccines' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Tiziana Life Sciences | N/A | N/A | N/A |
| VBI Vaccines | -2,837.73% | -36.69% | -28.29% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Tiziana Life Sciences and VBI Vaccines, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Tiziana Life Sciences | 0 | 0 | 2 | 0 | 3.00 |
| VBI Vaccines | 0 | 0 | 4 | 1 | 3.20 |
Tiziana Life Sciences currently has a consensus price target of $9.50, indicating a potential upside of 240.50%. VBI Vaccines has a consensus price target of $6.40, indicating a potential upside of 109.15%. Given Tiziana Life Sciences' higher probable upside, research analysts clearly believe Tiziana Life Sciences is more favorable than VBI Vaccines.
Insider and Institutional Ownership
52.1% of VBI Vaccines shares are owned by institutional investors. 10.5% of VBI Vaccines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
VBI Vaccines beats Tiziana Life Sciences on 8 of the 14 factors compared between the two stocks.
